STRO-004
Protein Target: Tissue Factor, TF
- Solid Tumors
- Undisclosed indication
SUTRO BIOPHARMA, INC.
Most recent annual filing: 2026-03-23
Pipeline (5 active programs)
STRO-227
Protein Target: PTK7, Protein Tyrosine Kinase 7
STRO-006
Protein Target: ITGB6, integrin alpha v beta 6
- Solid Tumors
- Undisclosed indication
Technology platforms
XpressCF · Vaxcyte
Cell-free protein synthesis platform enabling rapid production of complex biologics including ADCs, iADCs, bispecific ADCs, and dpADCs for oncology; also licensed to Vaxcyte for infectious disease vaccine development
XpressCF+ · Astellas
Site-specific conjugation platform enabling non-natural amino acid incorporation and precise dual-payload conjugation for homogeneous ADCs, iADCs, bispecific ADCs, and dpADCs in oncology
XpressCF
Cell-free protein synthesis platform used to generate site-specific and novel-format antibody-drug conjugates for oncology applications
Discontinued (1)
- luveltamab tazevibulin — undisclosed · strategic decision to deprioritize additional investment; development has since been terminated
Biotech Distilled coverage (1)
Articles open on Substack. Some deep dives are subscriber-only.